No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Zytiga is a drug used to treat prostate cancer. It is a type of androgen receptor inhibitor, which works by blocking the action of male hormones that can cause prostate cancer cells to grow. Zytiga is used in combination with prednisone, a steroid, to treat metastatic castration-resistant prostate cancer (mCRPC). It is also used in combination with other drugs to treat non-metastatic castration-resistant prostate cancer (nmCRPC).
Zytiga is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2011. It is now widely used in the treatment of prostate cancer, and is considered to be an important part of the treatment regimen for many patients.
The market for Zytiga is highly competitive, with several companies offering the drug. These include Johnson & Johnson, AbbVie, Astellas Pharma, and Pfizer. Show Less Read more
